Grants for Nonprofits - Health

The purpose of this funding opportunity is to support the development of Clinical Outcome Assessments (COA) for Substance Use Disorders (SUD). The COA development plan is expected to progress into the FDA drug development tool qualification program. This notice of funding opportunity (NOFO) utilizes the UG3/UH3Phased Innovation Awards Cooperative Agreement grant mechanism that includes two phases. The applications responding to this NOFO should contain a COA development plan that will cover both UG3 and UH3 phases. In the first 2-year UG3 phasethe project must have a set of operational milestones to be completed by the end of this period. Once NIDA program has evaluated the progress of the UG3 phase and determined that the UG3 phase has been successfully completed, it transitions to the UH3 phase to be funded for three additional years.The goal of this NOFO is to expand the armamentarium of COA that are FDA qualified as drug development tool (DDT) in the context of use (COI) of a SUD. Achieving this goal will greatly facilitate the development of treatments for SUDs. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

This funding opportunity provides financial support to nonprofit organizations in central Pennsylvania facing challenges due to federal funding instability, helping them maintain essential community services and improve quality of life.

This funding opportunity supports research institutions and organizations in developing innovative technologies to study how neural cell groups in rodents respond to addictive substances, aiming to deepen our understanding of addiction-related behaviors.

The GCI Suicide Prevention Grant Program, offered by The Alaska Community Foundation in partnership with GCI, aims to significantly reduce suicide rates and foster mental wellness throughout Alaska. This initiative aligns with the foundation's mission to strengthen community and personal connections, thereby promoting overall well-being. The program's core objective is to empower Alaskans, fostering a collaborative approach to community wellness and addressing a critical public health issue within the state. The target beneficiaries of this grant program are organizations committed to suicide prevention and mental wellness initiatives across all counties in Alaska. These include 501(c)3 public charitable organizations, faith-based organizations providing social services, federally recognized Tribes or Tribal nonprofit organizations, city governments or Boroughs, and K-12 schools. The program specifically excludes individuals, state or federal government agencies, for-profit organizations, private nonprofit organizations not meeting specific IRS designations, and activities that discriminate or involve religious indoctrination. The program prioritizes reaching communities that may lack easy access to crucial suicide prevention support. The program's priorities and focus areas are clear: empowering Alaskans to work together for community wellness, demonstrating measurable results and accountability, ensuring cultural sensitivity, and unifying communities. Emphasis is placed on projects that will have a tangible impact, particularly in underserved areas. This strategic focus ensures that funding is directed towards initiatives that are not only effective but also culturally appropriate and community-driven. Expected outcomes and measurable results include a reduction in suicide rates and an increase in mental wellness across Alaska. The grant program seeks to support projects that can demonstrate these results, emphasizing accountability in their implementation. The average grant award is approximately $5,000, with requests ranging from $1,000 to $10,000. This funding is intended to support project or operational costs, explicitly excluding capital projects, aligning with the foundation's strategic priority to directly impact and improve community health and resilience through targeted interventions.

This funding opportunity provides financial support to state and local governments, community organizations, and other eligible entities to improve access to long-term services and supports by enhancing their No Wrong Door systems through collaboration and modernization efforts.

This grant provides funding to organizations in Northern New York for projects that improve community well-being across various sectors, including health, education, arts, and environmental conservation.

This funding opportunity supports innovative research on new screening methods and treatments for severe conditions detectable in newborns, aimed at improving early detection and health outcomes.

This grant provides funding to nonprofit organizations and community groups in specific areas of O‘ahu for projects focused on environmental conservation, sustainability, and youth engagement.

This funding initiative provides $10,000 to small U.S. towns and nonprofit organizations to engage residents in shaping their community's future through a structured participatory model, requiring a matching contribution to ensure local investment.

This grant provides funding for institutional research training programs to develop skilled neuroscientists through comprehensive training in research, statistics, and communication, specifically targeting advanced graduate students and postdoctoral fellows.

This funding opportunity provides financial support to a wide range of organizations to create and implement community-based cooking demonstrations and nutrition education programs that promote healthy eating and improve cooking skills across the United States.

This funding opportunity supports academic organizations in the U.S. and Canada to lead early-phase cancer clinical trials, advancing innovative treatments and improving patient outcomes through collaborative research efforts.

This funding opportunity supports researchers in developing innovative theories and methods to better understand the complex interactions of genetic and non-genetic factors influencing human traits, particularly in relation to health and cancer risk.

This program provides financial assistance to small businesses in San Mateo County that have been impacted by the COVID-19 pandemic, helping them cover operating expenses and recover from revenue losses.

The grant titled "Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Data Coordinating Center (Collaborative U24 Trial Required)" is aimed at funding the development and implementation of a Data Coordinating Center to manage data, provide statistical support, and ensure overall coordination for a multi-site clinical trial focused on preventing cardiovascular disease in young adults at high risk, while also promoting community engagement, diversity, and health equity.

On November 6, 2018, California voters passed Proposition 4, the Children's Hospital Bond Act of 2018. The purpose of the program is to improve the health and welfare of California’s critically ill children, by providing a stable and ready source of funds for capital improvement projects for eligible hospitals. The California Health Facilities Financing Authority (CHFFA) is responsible for administering the program. Language in Proposition 4 identifies 13 children’s hospitals in California (referred to as “Children’s Hospitals”) as eligible for $1.35 billion in funding. The 13 Children's Hospitals designated by statute are the same as the 13 hospitals that received grants under the first two Children’s Hospital Programs also administered by CHFFA and enacted by Proposition 61 in 2004 and Proposition 3 in 2008. The 13 Children’s Hospitals consist of eight private nonprofit Children’s Hospitals and five University of California Children’s Hospitals. Grant awards for each private nonprofit Children’s Hospital was limited to $135 million, less costs of issuance and administrative costs. Grant awards for each University of California Children’s Hospital was limited to $54 million, less costs of issuance and administrative costs. Costs of issuance are $0.75 per $1,000 of the authorized grant award and administrative costs are $10.00 per $1,000 of the authorized grant award. Applications are accepted on an ongoing basis until June 30, 2033 and are due the first business day of each month, except October and November, and will be presented to the Authority the following month. For the month of October, Applications are due on October 7. Applications received on October 7 will be presented for Authority consideration at a regularly scheduled meeting in December or January. Applications are not accepted in November. Applications shall be submitted in duplicate to the Authority. Each Children’s Hospital may apply more than once. Submit completed Application by mail or in-person to: California Health Facilities Financing Authority Children’s Hospital Program 901 P Street Room 313 Sacramento, CA 95814

The "Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Older Adults" grant aims to fund a network of clinical trials that will study the safety and potential effectiveness of psychedelic drugs in treating chronic pain in older adults, with a focus on those aged 75 and above.

This funding opportunity provides financial support to organizations in rural communities that deliver cancer prevention, education, and early detection services to underserved populations.

This funding opportunity supports innovative research teams using non-human animal models to develop advanced methods for measuring and analyzing behavior in relation to environmental factors.

HIV infection and substance use are comorbid conditions that bidirectionally and synergistically influence the deleterious outcomes in people who suffer from substance use disorders (SUD). The persistence and transcriptional reactivation of HIV lead to the development of neuropathological complications. Strategies to address viral latency include silencing of HIV transcription and reactivation and clearance. The goal of this initiative is to support research aimed at (1) identification of targets and pathways by which transcriptional activity of HIV can be suppressed in HIV reservoirs including the CNS in people with SUD, and (2) application of emerging small molecule drug discovery approaches to identify novel compounds that can be utilized as pharmacological probes and as drugs to suppress HIV transcription in people with HIV-SUD comorbidity.